PB2343: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB VERSUS STANDARD OF CARE THERAPY IN RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA (OLYMPIA-4)
Eliza A. Hawkes,
Tae Min Kim,
Manjusha Namuduri,
Ashish Risal,
Biyi Shen,
Dina Flink,
Min Zhu,
Siobhán Nolan,
Jurriaan Brouwer-Visser,
Aafia Chaudhry,
Srikanth Ambati,
Hesham Mohamed,
Seok-Goo Cho
Affiliations
Eliza A. Hawkes
1 Olivia Newton-John Cancer Centre at Austin Health, Melbourne, Australia; School of Public Health & Preventative Medicine, Monash University, Melbourne, Australia
Tae Min Kim
2 Seoul National University Hospital, Seoul, Korea, Rep. of South
Manjusha Namuduri
3 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Ashish Risal
3 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Biyi Shen
3 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Dina Flink
3 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Min Zhu
3 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Siobhán Nolan
3 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Jurriaan Brouwer-Visser
3 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Aafia Chaudhry
3 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Srikanth Ambati
3 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Hesham Mohamed
3 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Seok-Goo Cho
4 Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea, Rep. of South
